Sentinel lymph node biopsy (SLNB) is the standard of axillary lymph node surgical staging in patients with early breast cancer.
The main goal of the study is to abandon axillary surgery in patients over 59 years old with early, luminal A, clinical lymph node negative breast cancer.
HER2-negative breast cancer (ER +/ PR +), Ki67 <= 30%, G1-2
age> 59 years.
morphologically confirmed diagnosis of breast cancer, IA-IIA stage
ECOG score 0-2.
Inconsistency with inclusion criteria.
stage T2-4, N1 or M1 cancer
severe uncontrolled concomitant chronic diseases or acute diseases
previous/concurrent malignancy or history of radiation therapy to the chest wall region